Mounjaro in India: the tirzepatide brands, the KwikPen, the dose steps and what is not sold here

Yes. Mounjaro has been sold in India since 20 March 2025, on a doctor's prescription^1,4. Lilly sells it here in two forms: single-dose vials for certain strengths, and the KwikPen, a prefilled pen with four once-weekly doses⁴.

What is and is not sold in India, from Indian reports, PharmEasy's listings and the US labels^4,7,10.

Facts checked on 29 October 2026.

By Cipla's stock-exchange filing of 23 October 2025, Lilly manufactures and supplies Yurpeak; Cipla distributes and promotes it as the second brand of tirzepatide in India². The filing says the price will be the same as Mounjaro². The entity table shows the same MRPs for both^4,6.

Cipla launched Yurpeak on 11 December 2025, after Lilly received approval from the Drugs Controller General of India (DCGI), BioVoice reported^5,12. Yurpeak is not a generic².

The MRPs above were listed in October 2026, after the GST cut of 22 September 2025, from 12 % to 5 % on most medicines^4,15. For the semaglutide brands, Wegovy, Poviztra, Ozempic and the generics, see GLP-1 medicines in India^16,17,18.

PTI reported two Indian uses for Mounjaro: type 2 diabetes, and weight management in adults whose body mass index (BMI) is 30 or more, or 27 or more alongside a weight-related condition⁸. Cipla's filing for Yurpeak repeats the indication and the cut-offs of 30 and 27².

In June 2026, CDSCO's expert committee kept the cut-off: removing it was not appropriate, it said, since US and Asian populations define obesity and overweight differently⁹. A government backgrounder of April 2026 defines overweight as a BMI of 23.00 to 24.99 and obesity as 25 or more¹⁹. So you can be obese by India's definition and still sit below the cut-off in Mounjaro's Indian indication^8,19.

The US Zepbound label also lists moderate to severe obstructive sleep apnoea in adults with obesity¹³; PTI reported no such use for India⁸. Our page on who should not take semaglutide sets India's BMI definition against the label cut-offs in more detail.

The Mounjaro KwikPen sold in India holds 4 weekly doses at one strength, so one pen covers 4 weeks^3,4. Both Indian pens come in the six strengths listed in the first table^2,4.

How many doses does one Mounjaro KwikPen contain?

Four. The US Mounjaro label says each KwikPen holds 2.4 mL and provides 4 doses of 2.5, 5, 7.5, 10, 12.5 or 15 mg, each dose 0.6 mL¹⁰. Never share a KwikPen between patients, even with a new needle, the US label says¹⁰.

Is Mounjaro 2.5 mg a starting dose?

Yes, under the US labels. In India, 2.5 mg is sold as a KwikPen and a vial⁴. The US Mounjaro label starts tirzepatide at 2.5 mg once weekly¹⁰. The US Zepbound label, which covers weight management, keeps 2.5 mg for 4 weeks, then raises the dose in 2.5 mg steps with at least 4 weeks on each¹³. Its maintenance doses for weight reduction are 5, 10 or 15 mg a week; the maximum for all uses is 15 mg a week¹³. The US Mounjaro label raises the dose in the same 2.5 mg steps when more blood-sugar control is needed, up to the same adult maximum of 15 mg¹⁰. These are US label schedules; your doctor sets the dose. The US Zepbound label does not recommend tirzepatide together with another tirzepatide product or any GLP-1 medicine¹³.

If a dose is missed, the US Mounjaro label says to take it as soon as possible within 4 days (96 hours)¹⁰. After that, it says to skip it and take the next dose on the usual day¹⁰.

Storage, from the same US label: keep an unopened KwikPen in the refrigerator at 2°C to 8°C¹⁰. At room temperature up to 30°C, an unopened pen is thrown away after 30 days¹⁰. An opened pen is thrown away after 30 days in total at room temperature, 30 days after first use, or after 4 doses, even if medicine remains¹⁰. For single-dose pens and vials, such as the Mounjaro vials sold in India, the US label's limit at up to 30°C is 21 days in total^4,10. Check where you keep it against that 30°C limit¹⁰.

Lilly's KwikPen steps are on our pen page: mounjaro kwikpen how to use. Semaglutide doses are in the semaglutide dose schedule.

In SURMOUNT-1, adults without diabetes lost an average of 15.0 % of their weight on 5 mg, 19.5 % on 10 mg and 20.9 % on 15 mg at 72 weeks²⁰. The placebo group lost 3.1 % on average²⁰. The trial enrolled 2,539 adults with an average BMI of 38.0; Eli Lilly supported it²⁰. Its entry rule, a BMI of 30 or more, or 27 or more with a weight-related problem, matches the cut-offs in Mounjaro's Indian indication^8,20. Half of those on 10 mg and 57 % on 15 mg lost at least 20 % of their weight, against 3 % on placebo²⁰.

In adults with obesity and type 2 diabetes (SURMOUNT-2), the average losses at 72 weeks were 12.8 % on 10 mg and 14.7 % on 15 mg, against 3.2 % on placebo²¹.

In the head-to-head trial, SURMOUNT-5, average weight loss at 72 weeks was 20.2 % on tirzepatide against 13.7 % on semaglutide, in 751 adults with obesity and without type 2 diabetes²². Eli Lilly funded it, and it was open-label: everyone knew which medicine they were taking^22,23.

In SURMOUNT-4, adults who completed a 36-week lead-in on tirzepatide had lost 20.9 % on average²⁴. Those then switched to placebo regained 14.0 % on average by week 88, while those who stayed on tirzepatide lost a further 5.5 %²⁴.

How much weight can you lose on tirzepatide in 3 months?

Most trials this page cites report results at 72 weeks²⁰. The first 20 weeks of SURMOUNT-1 were spent raising the dose in steps²⁰. So this page gives no three-month number. Our tirzepatide vs semaglutide page compares the two medicines and their Indian brands side by side, and stopping mounjaro weight gain covers the regain data.

Mounjaro side effects: the label rates in brief

In the US Zepbound label's weight-loss trials, nausea affected 25 % on 5 mg, 29 % on 10 mg and 28 % on 15 mg, against 8 % on placebo¹³. Vomiting: 8, 11 and 13 % against 2 %; diarrhoea 19, 21 and 23 % against 8 %; constipation 17, 14 and 11 % against 5 %¹³. Hair loss: 4 to 5 % against 1 %¹³. In two pooled trials, 4.8 %, 6.3 % and 6.7 % of people on those doses stopped for good because of side effects, against 3.4 % on placebo¹³. Most stopped in the first few months, for digestive effects¹³.

Serious but less common: the UK's National Health Service (NHS) lists pancreatitis and gallstones or an inflamed gallbladder²⁵. The US label's boxed warning, its strongest kind, says tirzepatide caused thyroid C-cell tumours in rats; whether it does so in people is unknown¹³. The US label says people with a personal or family history of medullary thyroid cancer, or with MEN 2, an inherited gland-tumour condition, must not take it¹³. Tell your doctor about a lump in the neck, trouble swallowing, shortness of breath or a hoarse voice that does not go away¹³.

Signs that need help now

A swollen throat or tongue, a raised itchy rash or difficulty breathing can be a serious allergic reaction: call 112, India's emergency number, now^25,26. Severe stomach pain that does not go away, with or without vomiting: the US Medication Guide says stop the medicine and call your doctor right away¹³. Pain in the upper stomach, fever, yellow skin or eyes, or clay-coloured stools: the same US Medication Guide says tell your doctor right away¹³. With insulin or a sulfonylurea, the US label warns that tirzepatide may raise the risk of low blood sugar, including severe episodes¹³. Signs include sweating, a fast heartbeat, dizziness or confusion, the NHS says²⁵. Treat it quickly with a sugary drink, such as a small glass of fruit juice, as the NHS advises; then tell your doctor²⁷. Report any suspected side effect to the helpline of India's Pharmacovigilance Programme (PvPI), 1800 180 3024, on working days, as well as to your doctor^28,29. More on Mounjaro side effects.

PharmEasy lists Mounjaro and Yurpeak as Schedule H medicines, not sold over the counter^4,6. Who may write the prescription is less settled. The health ministry said on 24 March 2026 that GLP-1 weight-loss drugs were approved on condition that an endocrinologist or internal medicine specialist prescribes them, or for some uses a cardiologist³⁰. For tirzepatide, CDSCO's expert committee set that condition in April 2023, when it recommended permission to import and market the six strengths³¹. It is an approval condition; whether it binds every pharmacy as a national rule is not confirmed³¹.

The government's April 2026 backgrounder advises you to consult a qualified specialist first and to obtain these medicines on prescription, through legitimate, regulated channels¹⁹. PharmEasy says fake GLP-1 pens have been reported in India in 2026³². In April 2026, Reuters reported a claim it could not verify: Haryana's drug regulator said it had seized over 260 suspected fake Mounjaro pens near New Delhi³³.

On 10 March 2026, CDSCO issued an advisory to all manufacturers that prohibits surrogate advertisements and indirect promotion of GLP-1 weight-loss drugs³⁰. That is one reason this page names both brands and recommends neither. Your doctor decides whether tirzepatide suits you, which brand, and at what dose. Talk to a Zelta specialist to start that conversation.

Is Mounjaro a GLP-1 agonist? Yes. It switches on two gut-hormone receptors, GIP and GLP-1, the US label says¹³; the UK's NHS calls it a dual agonist²⁵.

What GLP-1 medications are available in India? Tirzepatide as Mounjaro and Yurpeak; semaglutide as Wegovy, Poviztra, Ozempic, Rybelsus and the generic brands sold since March 2026^{1,5,16,17,18,34,35}. Dulaglutide and liraglutide are also still sold³⁶. The full list is on GLP-1 medicines in India.

Is semaglutide better or worse than tirzepatide? In the head-to-head trial SURMOUNT-5, tirzepatide gave more weight loss: 20.2 % against 13.7 % on average at 72 weeks²². Lilly, tirzepatide's maker, funded the trial and ran it open-label^22,23. tirzepatide vs semaglutide has the detail.

Do people lose more weight on Mounjaro or Ozempic? No trial in our sources compares Mounjaro with Ozempic. SURMOUNT-5 compared tirzepatide with semaglutide at 1.7 or 2.4 mg in adults with obesity and without type 2 diabetes; in India, 2.4 mg is sold as Wegovy^22,37.

Is Wegovy available in India? Yes, as an injection: Novo Nordisk launched Wegovy here on 24 June 2025¹⁶. We found no Indian approval or launch of the Wegovy pill by 20 October 2026³⁸. See Wegovy in India.

Two more questions, from the pharmacy pages readers land on:

Is there a generic Mounjaro in India? No. Tirzepatide is still under patent protection in India, Bloomberg reported in April 2026⁷.

Is Zepbound available in India? Zepbound is the US brand name of tirzepatide for weight management¹³. In India the two brands are Mounjaro and Yurpeak, as Cipla's filing records².